logo
Plus   Neg
Share
Email

Salzgitter Agrees Feasibility Study For Direct Reduction Of Iron Ore At Wilhelmshaven

Salzgitter AG (SZGPF.PK,SZGPY.PK) said that it reached an agreement with the Federal State of Lower Saxony, the City of Wilhelmshaven and the industrial partners Rhenus and Uniper to conduct a feasibility study for the construction of a direct reduced iron or DRI plant with an upstream hydrogen electrolyzer at the deepwater port of Wilhelmshaven in Lower Saxony.

The company noted that the study includes potentially building a DRI plant and developing the necessary infrastructure for supplying it with raw materials, natural gas and hydrogen. The results are to be available by March 31, 2021 at the latest.

Salzgitter AG's CEO Prof. Dr.-Ing. Heinz J?rg Fuhrmann said, "This is another concrete step in our process of evolving toward low CO2, hydrogen-based steel production underpinned by our prestigious SALCOS (SAlzgitter Low CO2 Steelmaking) technology concept."

The target envisaged is to produce two million directly reduced iron castings per year that will be transported by rail to Salzgitter and processed there into high-grade, environmentally compatible strip steel products in Salzgitter Flachstahl GmbH's integrated steelworks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT